Human immunodeficiency virus type 1 Gag, Pol, and Env antigenic epitopes (HIV-1 Gag/Pol/Env epitopes)

The HIV-1 Gag, Pol, and Env antigenic epitopes represent the primary targets for the development of preventive and therapeutic vaccines against the Human Immunodeficiency Virus type 1. The Gag (group-specific antigen) polyprotein is processed into structural proteins such as matrix (p17), capsid (p24), and nucleocapsid (p7), which are essential for viral assembly and maturation. The Pol (polymerase) polyprotein provides critical enzymes including reverse transcriptase, integrase, and protease, which facilitate the viral life cycle within the host cell. The Env (envelope) glycoprotein, consisting of gp120 and gp41 subunits, mediates viral attachment and entry into host CD4+ T-cells and is the primary target for neutralizing antibodies. Because these proteins contain highly conserved regions across different HIV strains, they are utilized in various vaccine platforms to elicit both humoral and cellular immune responses. Therapeutic strategies targeting these epitopes aim to reduce the latent viral reservoir and provide long-term control of the infection without the continuous need for antiretroviral therapy.

Other names

HIV-1 polyprotein epitopesGag-Pol-Env antigensHIV-1 structural and enzymatic protein epitopesHIV-1 vaccine antigens

Induction of broad neutralizing antibodies (bNAbs) and virus-specific T-cell responses to inhibit viral entry, replication, and to clear infected cells.